Anthem Biosciences Quarterly Results for Trading Insights
In Sept 2025, Anthem Biosciences (ANTHEM) reported revenue ₹598 Cr and net profit ₹173 Cr — revenue +8.1% YoY. For annual financials, live price and key ratios, visit Anthem Biosciences share price screener.
ANTHEM Quarterly Results — Revenue, Profit & EPS Highlights
Anthem Biosciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore ANTHEM share price history to track price trends across different timeframes.
- Revenue of ₹598 Cr in Sept 2025 (+20.3% vs Mar 2025, +8.1% vs Sept 2024)
- Net Profit of ₹173 Cr in Sept 2025 (+108.4% vs Mar 2025, +6.8% vs Sept 2024)
- EBITDA of ₹266 Cr in Sept 2025 (+27.3% vs Mar 2025)
- Operating Margin of 40.0% in Sept 2025 (+0.0pp vs Mar 2025)
- Earnings Per Share of ₹3.09 in Sept 2025 (+108.8% vs Mar 2025)
Anthem Biosciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ANTHEM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 598 | 497 | 563 | 457 | 553 | 20.3% | 8.1% |
| Net Profit (₹ Cr) | 173 | 83 | 136 | 93 | 162 | - | - |
| EBITDA (₹ Cr) | 266 | 209 | 214 | 165 | 223 | - | - |
| EPS (₹) | 3.09 | 1.48 | 2.43 | 1.65 | 2.90 | - | - |
| Operating Margin (%) | 40.0% | 40.0% | 35.0% | 31.0% | 37.0% | - | - |
ANTHEM Share Price Trend — 1-Year Movement Across Quarterly Results
Anthem Biosciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with ANTHEM fair value estimate to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ANTHEM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Anthem Biosciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.9 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.9 |
|
Divis Laboratories
Mar 2026 |
₹175,434.91 Cr | 6787.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 239.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹149,924.56 Cr | 4457.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 387.2 |
|
Zydus Life Science
Mar 2026 |
₹109,226.70 Cr | 1085.5 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 85.8 |
|
Cipla
Mar 2026 |
₹109,195.79 Cr | 1415.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.1 |
All amounts in ₹ Crores